ProKidney

PROK

Market cap $333M

2.35 USD

-0.11

4.47%

At close Updated Mar 5, 4:00 PM EST

Pre-market

After hours

2.35

0.00

1 day

-4.47%

5 days

5.86%

1 month

35.84%

3 months

0.43%

6 months

4.44%

Year to date

5.38%

1 year

125.96%

5 years

-76.76%

10 years

-76.76%

About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Employees: 204

Healthcare Biotechnology